Drug Profile
Research programme : monoclonal antibody therapeutics - Centessa Pharmaceuticals
Latest Information Update: 25 Feb 2021
Price :
$50
*
At a glance
- Originator Capella BioScience
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Fibrosis; Inflammatory bowel diseases
Most Recent Events
- 16 Feb 2021 Capella BioScience has merged with Centessa Pharmaceuticals to form Centessa Pharmaceuticals
- 28 Apr 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in United Kingdom